



## Phosphorus P 32

Revised: August 17, 2020.

CASRN: 14596-37-3

P :[32]

## Drug Levels and Effects

### Summary of Use during Lactation

Information in this record refers to the use of phosphorus P 32 as a therapeutic agent. No information is available on the use of phosphorus P 32 during breastfeeding. Use of phosphate P 32 as a skin patch to treat skin cancers poses no risk to breastfed infants after removal of the patch from the mother's skin

### Drug Levels

Phosphorus P 32 decays by beta emission with an energy of 1.709 MeV and a half-life of 14.3 days.[1]

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## References

1. Mountford PJ, Wells CP, Hall FM, et al. Potential radiation dose to a breast-fed infant following administration of sodium <sup>32</sup>P-phosphate to the mother. Nucl Med Commun. 1984;5:473-6. PubMed PMID: 6531156.

## Substance Identification

### Substance Name

Phosphorus P 32

### CAS Registry Number

14596-37-3

### Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Phosphorus Radioisotopes